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Phase I/II trial of weekly bortezomib with lenalido-
mide and dexamethasone in first relapse or primary
refractory myeloma 
The use of the proteasome inhibitor bortezomib and
immunomodulatory drugs such as thalidomide and
lenalidomide have markedly improved outcome in
patients with multiple myeloma (MM).1 However, the
majority of patients will eventually relapse, necessitating
salvage therapy. 
HOVON 86 is a dose escalating phase I-II study, evalu-
ating the feasibility (phase I) and efficacy (phase II) of
once weekly escalated doses of bortezomib and lenalido-
mide in combination with fixed dose dexamethasone fol-
lowed by lenalidomide maintenance in patients with
MM in first relapse or refractory after first-line therapy.
In previous trials bortezomib was explored predominant-
ly in a twice weekly schedule. We wished to explore once
weekly bortezomib with the possibility to increase the
dose of bortezomib in combination with an escalated
dose of lenalidomide and dexamethasone.
The maximum tolerated dose (MTD) and recommend-
ed dose level (RDL) were determined according to a `3+3’
dose escalation scheme at bortezomib 1.6mg/m2 intra-
venously (IV); lenalidomide 10mg; dexamethasone 20mg,
followed by lenalidomide maintenance. 
44 out of 70 (63%) eligible patients started mainte-
nance. ORR on protocol was 89%, with 71% ≥VGPR,
including 27% CR. The median number of cycles to
achieve ≥PR was 1. The median progression-free survival
(PFS) and overall survival (OS) rates were 19 and 42
months, respectively. Hematologic toxicity CTC grade 3-
4 occurred in 30% of patients and 17% of patients devel-
oped polyneuropathy (PN) grade 3-4. 
This study was approved by the ethics committees of
the Erasmus MC Cancer Institute and the participating
sites. All patients gave written informed consent, and the
trial was conducted according to the European Clinical
Trials Directive 2005 and the Declaration of Helsinki,
trial EudraCT number: 2007-002533-37. 
Patients were eligible for this study if they were aged
≥18 years with primary refractory MM or first relapse
after prior achievement of an objective response (≥PR) on
first-line treatment. Main exclusion criteria included prior
therapy with bortezomib or lenalidomide, the presence
of PN or neuropathic pain grade ≥2 as defined by NCI
CTCAE version 3.0. 
Bortezomib was administered intravenously at a start-
ing dose of 1.3 mg/m2 on days 1, 8 and 15 of a 28-day
cycle. During the phase I part, the bortezomib dose was
escalated to 1.6 mg/m2, while 
lenalidomide was administered orally starting at 10
mg/day, days 1-21. The dose of lenalidomide was
planned to increase by 5 mg starting at dose level 3 and
4. Dexamethasone fixed dose was 20 mg on days 1, 2, 8,
9, 15 and 16. During the phase I part, the MTD and the
RDL for phase II of bortezomib and lenalidomide were
determined using a slightly modified `3+3’ dose escala-
tion scheme. When 3 or 6 patients were entered, inclu-
sion was discontinued until the dose-limiting toxicity
(DLT) had been determined at day 22 of cycle I. 
The primary objective of the phase I study was to
determine the DLT, MTD and RDL. The secondary objec-
tive was to evaluate toxicity. For the phase II part the
(s)CR+VGPR rate was considered as the primary end-
point. Secondary endpoints included ORR defined as
sCR, CR, VGPR and PR, DoR, PFS, OS, TTNT, and toxi-
city. Furthermore, PFS and OS from the start of mainte-
nance were also estimated. 
81 relapsed MM patients were enrolled from
September 2008 to January 2012. Of these 81 patients, 4
were non-eligible based on not having measurable dis-
ease. Baseline characteristics at registration of the 77 eli-
gible patients are documented (see Table 1). 
13 patients participated in the phase I part of the study.
The DLT was reached at the third dose level with two
grade 3 non-hematological adverse events; there were no
DLTs in dose level 1 and 2. Therefore, the RDL for phase
II was established at dose level 2: bortezomib 1.6 mg/m2,
lenalidomide 10 mg, dexamethasone 20 mg. 
In patients who had achieved at least VGPR after a
maximum of 6 cycles, treatment was continued with 2
cycles as consolidation.  All patients from phase I and
phase II who had achieved at least a PR after induction,
received maintenance with lenalidomide at a dose of 10
mg on days 1-21, which started at day 29 of the last
cycle. Maintenance cycles were repeated at 28-day inter-
vals until relapse, progression or the occurrence of a med-
ical condition that required stopping the treatment.
44 out of 70 (63%) patients treated at the RDL in phase
I and II completed 6 induction and 2 consolidation cycles
and started with lenalidomide maintenance, as shown in
Figure 1. The median number of induction treatment
cycles is 3 (range 1-6) in phase I and 4 (range 1-8) in phase
II. The median duration of maintenance is 12 months
(range 11 to 45 months) in phase I and 19 months (range
1-37) in phase II. 
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Figure 1. Flow diagram HOVON 86. The treatment data is summarized by the
flow diagram. It shows the number and proportion of patients in a specific
treatment cycle, and the number of off protocol patients along with the reason
for going out of protocol treatment. The diagram is generated for all included
patients in both phases together.
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Table 1. Patients’ characteristics.
I II III IV Total
Age
Median 65 62 68 67 66
Range 61-68 59-69 61-75 46-84 46-84
Number 2 6 5 64 77
Albumin
Median 43.5 40.0 41.0 39.0 39.0
Range 40.0-47.0 36.0-43.0 33.0-47.1 21.0-50.0 21.0-50.0
Number 2 5 5 61 73
Sex
n % n % n % n %
M 1 50% 2 33% 4 80% 42 66% 49 64%
F 1 50% 4 67% 1 20% 22 34% 28 36%
Serum b2-microglobulin
≤3 1 50% 4 67% 2 40% 30 47% 37 48%
>3 - 1 17% 3 60% 22 34% 26 34%
unknown 1 50% 1 17% - 12 19% 14 18%
ISS
I 1 50% 4 67% 2 40% 30 47% 37 48%
II - 1 17% 2 40% 17 27% 20 26%
III - - - - 1 20% 4 6% 5 6%
unknown 1 50% 1 17% - - 13 20% 15 19%
Type of first-line treatment
VAD - - - - - - 10 16% 10 13%
MP - - - - - - 2 3% 2 3%
TAD - - - - - - 14 22% 14 18%
MPT - 1 17% 2 40% 21 33% 24 31%
Other 2 100% 5 83% 3 60% 17 27% 27 35%
Prior HDM/ASCT
No - 2 33% 2 40% 52 81% 56 73%
Yes 2 100% 4 67% 3 60% 12 19% 21 27%
Prior MP/MPT
No 2 100% 5 83% 3 60% 40 63% 50 65%
Yes - 1 17% 2 40% 24 38% 27 35%
Best response to first-line treatment
sCR - - - - - - 3 5% 3 4%
CR 1 50% 1 17% 2 40% 12 19% 16 21%
VGPR - 3 50% 1 20% 18 28% 22 29%
PR 1 50% 1 17% 2 40% 24 38% 28 36%
SD - 1 17% - - 4 6% 5 6%
unknown - - - - - - 2 3% 2 3%
other(*) - - - - - - 1 2% 1 1%
t(4;14)(p16;q32)
No - - 2 33% 2 40% 25 39% 29 38%
Yes - - - - 1 20% 3 5% 4 5%
unknown 2 100% 4 67% 2 40% 36 56% 44 57%
t(14;16)(q32;q23)
No - - - - - - 17 27% 17 22%
Yes - - - - 2 40% 1 2% 3 4%
unknown 2 100% 6 100% 3 60% 46 72% 57 74%
1q gain and/or 1p loss 
No - - 1 17% - - 24 38% 25 32%
Yes - - 1 17% 1 20% 14 22% 16 21%
unknown 2 100% 4 67% 4 80% 26 41% 36 47%
13q14 loss
No 1 50% 3 50% - - 27 42% 31 40%
Yes - - 1 17% 3 60% 16 25% 20 26%
unknown 1 50% 2 33% 2 40% 21 33% 26 34%
17p13 loss
No - - 2 33% 2 40% 40 63% 44 57%
Yes - - - - - - 5 8% 5 6%
unknown 2 100% 4 67% 3 60% 19 30% 28 36%
Extra copy of 9 and/or 11
No 1 50% 2 33% - - 24 38% 27 35%
Yes 1 50% 1 17% 2 40% 17 27% 21 27%
unknown - - 3 50% 3 60% 23 36% 29 38%
Group I: Phase 1, dose level 1; Group II: Phase 1, dose level 2; Group III: Phase 1, dose level 3;  Group IV: Phase 2, dose level 2. Cytogenetic abnormalities were determined by
FISH.  AD: vincristine, adriamycin, dexamethasone; MP: melphalan, prednisone; TAD: thalidomide,  adriamycin, dexamethasone; MPT: melphalan, prednisone, thalidomide; sCR:
stringent complete response; CR: complete response; VGPR: very good partial response; PR: partial response; SD: stable disease; ORR: overall response rate.
49 out of 70 patients (70%) went off protocol, while
the remaining 21 (30%) patients were still receiving
maintenance treatment at the time of data analysis. The
main reasons for going off protocol were progression or
relapse (n=25/70) (36%) and/or toxicity (n=12/70) (17%). 
Of the 70 patients treated at the RDL in phase I (n=6)
and in phase II (n=64), the (s)CR +VGPR rate after induc-
tion was 64% (95%CI: 53%-76%), including 20% CR
(95%CI:10%-30%). The ORR was 89% (95%CI: 81%-
96%). The median number of cycles to reach at least a PR
was 1 (range 1-6). The median number of cycles to best
response during induction was 2 (range 1-8).
The analysis of PFS and OS measured from study entry
was available for all patients. At the time of final analysis
45 out of 70 patients were still alive with a median fol-
low-up time of 25 months, range 14-49 months. There
were 25 (36%) deaths of which 17 (24%) patients died
from progression. The median PFS and OS were 19
months (range 1-49 months) and 42 months (range 1-49
months), respectively. The median DoR was 28 months
(range 2-48 months). The median TTNT was 19 months
(range 1-49 months), (Figure 2A-D).
The median duration of maintenance was 19 months
(range 1-45 months). Median PFS and OS from the start
of maintenance were 23 months (range 1-45 months),
and 36 months (range 3-45 months), respectively (Figure
2 E,F).  
Prognostic markers considered in a logistic regression
analysis of response and the Cox regression analyses of
PFS and OS included sex, age (≥65 vs. <65 years), albu-
min, serum b2-microglobulin (>3 vs. ≤3mg/l), ISS (II+III
vs. I), as well as FISH markers t(4;14), t(14;16), gain of
1q21 and/or loss of 1p, del(17p13), and trisomy 9 and/or
11. Other factors included: prior thalidomide use, prior
HDM/ASCT, and response to first-line treatment. The
analyses were based on all available data. FISH analysis
was done at inclusion in HOVON 86. 
It was observed that an extra copy of chromosome 9
and/or 11 was associated with reaching a CR (OR, 0.11;
95%CI, 0.01-0.98; P=0.02). Furthermore, prior thalido-
mide treatment had a significant negative impact on
achievement of VGPR or CR (OR, 0.15; 95%CI, 0.04-
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Figure 2. Kaplan-Meier survival
curves among patients with multiple
myeloma. (A) Progression-Free
Survival; (B) Overall Survival; (C)
Duration of response; (D) Time to
next treatment; (E) Progression-Free
Survival from start of maintenance;
(F) Overall Survival from start of main-
tenance.
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0.54; P=0.003). No significant association of any other
risk factor with PFS or OS was observed.
Hematologic and non-hematologic adverse events
(AEs) NCI CTCAE grade 1-4 occurred in 69 out of 70
patients. 17% had to stop treatment early due to AEs.
Hematologic AEs of grade 1-4 occurred in 47% of
patients, with 30% being grade 3-4 events. Dose reduc-
tions were performed in 11 out of 17 (65%) patients.
41 out of 70 (59%) patients developed PN grade ≥1.
41% patients had grade 1-2, and 17% patients had grade
3-4 PN. The median time to develop PN grade ≥1 was
123 days, and to develop a maximum grade PN was 168
days. In patients who experienced bortezomib related PN
and neuropathic pain, dose interruptions/ adjustments
were effectuated according to protocol based on the
guidelines developed for bortezomib.2-4 
There were 6 incidences of second primary malignan-
cies (SPM) in 5 patients. SPMs included 3 invasive solid
tumors, 1 MDS-RAEB-2 and 2 skin cancers, i.e. basal cell
carcinoma and squamous cell carcinoma. The median
time to first incidence of SPM was 17 months (range 8-35
months).                 
Previous trials that tested the efficacy of combinations
of novel drugs have shown an ORR of 63-74%.5-9 The
bortezomib, lenalidomide and dexamethasone regimen
tested in the current trial compares favorably to these
results. In the study done by Richardson et al., 64 patients
with relapsed or relapsed and refractory MM received up
to eight 21-day cycles of bortezomib 1.0 mg/m2, lenalido-
mide15 mg/day and dexamethasone followed by mainte-
nance therapy. ORR was 64% including patients who
had been exposed to either agent alone. The median PFS
and OS at a median follow-up of 44 months were 9.5 and
30 months, respectively.10 The comparisons across stud-
ies should be interpreted with caution because of poten-
tial confounding factors such as differences in patient
characteristics and prior therapies, as mentioned. 
We observed that the higher dose bortezomib (1.6
mg/m2 weekly) was associated with 17% grade 3-4 PN,
higher than that observed in the study by Richardson 
et al. who reported an incidence of 3% grade 3 PN using
a bortezomib dose of 1.0 mg/m2.10,11 Of note, in our study
bortezomib was administered intravenously, which is dif-
ferent from the current standard, i.e. 1.3 mg/m2 subcuta-
neously. 
A weekly escalated dose of bortezomib 1.6 mg/m2 plus
lenalidomide 10 mg/day, combined with low-dose dex-
amethasone is a feasible, effective treatment for relapsed,
refractory MM patients. Future applications of this sched-
ule may benefit from subcutaneous dosing in order to
reduce the incidence of PN. 
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